Long-term cardiovascular risks and the impact of statin treatment on socioeconomic inequalities: a microsimulation model
Runguo Wu,Claire Williams,Junwen Zhou,Iryna Schlackow,Jonathan Emberson,Christina Reith,Anthony Keech,John Robson,Jane Armitage,Alastair Gray,John Simes,Colin Baigent,Borislava Mihaylova,CTT Collaboration secretariat CTT Collaboration trialists: A to Z trial (phase Z) AFCAPS/TEXCAPS (AirForce/Texas Coronary Atherosclerosis Prevention Study)ALERT (Assessment of Lescol in Renal Transplantation)ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial)ALLIANCE (Aggressive Lipid-Lowering Initiation Abates New Cardiac Events)ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial)ASPEN (Atorvastatin Study for the Prevention of Coronary Heart Disease Endpoints in Non-Insulin Dependent Diabetes Mellitus)AURORA (A study to evaluate the Use of Rosuvastatin in subjects On Regular haemodialysis: an Assessment of survival and cardiovascular events)CARDS (Collaborative Atorvastatin Diabetes Study)CARE (Cholesterol And Recurrent Events Study)CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure)4D (Die Deutsche Diabetes Dialyse Studie)GISSI (Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto miocardico) Heart Failure and Prevention trialsHOPE-3HPS (Heart Protection Study)IDEAL (Incremental Decrease in Endpoints through Aggressive Lipid-lowering)JUPITER (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin)LIPID (Long-term Intervention with Pravastatin in Ischaemic Disease)LIPS (Lescol Intervention Prevention Study)Post-CABG (Post-Coronary Artery Bypass Graft Study)PROSPER (Prospective Study of Pravastatin in the Elderly at Risk)PROVE-IT (Pravastatin or Atorvastatin Evaluation and Infection Therapy)SEARCH (Study of Effectiveness of Additional Reductions in Cholesterol and Homocysteine)SPARCL (Stroke Prevention by Aggressive Reduction in Cholesterol Levels)4S (Scandinavian Simvastatin Survival Study)TNT (Treating to New Targets)WOSCOPS (West of Scotland Coronary Prevention Study)Other CTT Collaboration members,Elizabeth Barnes,Lisa Blackwell,Rory Collins,Kelly Davies,Jordan Fulcher,Heather Halls,William G Herrington,Lisa Holland,Adrienne Kirby,Rachel O'Connell,David Preiss,Kate Wilson,Michael Blazing,Eugene Braunwald,James de Lemos,Sabina Murphy,Terje R Pedersen,Marc Pfeffer,Harvey White,Stephen Wiviott,Michael Clearfield,John R Downs,Antonio Gotto Jr,Stephen Weis,Bengt Fellström,Hallvard Holdaas,Alan Jardine,David Gordon,Barry Davis,Curt Furberg,Richard Grimm,Sara Pressel,Jeffrey L Probstfield,Mahboob Rahman,Lara Simpson,Michael Koren,Björn Dahlöf,Ajay Gupta,Neil Poulter,Peter Sever,Hans Wedel,Robert H Knopp,Stuart Cobbe,Roland Schmieder,Faiez Zannad,D John Betteridge,Helen M Colhoun,Paul N Durrington,John Fuller,Graham A Hitman,Andrew Neil,C Morton Hawkins,Lemuel Moyé,Frank Sacks,John Kjekshus,John Wikstrand,Christoph Wanner,Vera Krane,Maria Grazia Franzosi,Roberto Latini,Donata Lucci,Aldo Maggioni,Roberto Marchioli,Enrico B Nicolis,Luigi Tavazzi,Gianni Tognoni,Jackie Bosch,Eva Lonn,Salim Yusuf,Louise Bowman,Martin Landray,Sarah Parish,Richard Peto,Peter Sleight,John Jp Kastelein,Robert Glynn,Wolfgang Koenig,Jean MacFadyen,Paul M Ridker,Stephen MacMahon,Ian Marschner,Andrew Tonkin,John Shaw,Patrick W Serruys,Genell Knatterud,Gerard J Blauw,Ian Ford,Peter Macfarlane,Chris Packard,Naveed Sattar,James Shepherd,Stella Trompet,Christopher P Cannon,Richard Bulbulia,Richard Haynes,Pierre Amarenco,K Michael Welch,Lars Wilhelmsen,Philip Barter,John LaRosa,Sharon Kean,Michele Roberston,Robin Young,Hiroyuki Arashi,Robert Clarke,Marcus Flather,Shinya Goto,Uri Goldbourt,Jemma Hopewell,G Kees Hovingh,George Kitas,Connie Newman,Marc S Sabatine,Gregory G Schwartz,Liam Smeeth,Jonathan Tobert,John Varigos,Junichi Yamamguchi
DOI: https://doi.org/10.3399/BJGP.2023.0198
2024-02-29
Abstract:Background: UK cardiovascular disease (CVD) incidence and mortality have declined in recent decades but socioeconomic inequalities persist. Aim: To present a new CVD model, and project health outcomes and the impact of guideline-recommended statin treatment across quintiles of socioeconomic deprivation in the UK. Design and setting: A lifetime microsimulation model was developed using 117 896 participants in 16 statin trials, 501 854 UK Biobank (UKB) participants, and quality-of-life data from national health surveys. Method: A CVD microsimulation model was developed using risk equations for myocardial infarction, stroke, coronary revascularisation, cancer, and vascular and non-vascular death, estimated using trial data. The authors calibrated and further developed this model in the UKB cohort, including further characteristics and a diabetes risk equation, and validated the model in UKB and Whitehall II cohorts. The model was used to predict CVD incidence, life expectancy, quality-adjusted life years (QALYs), and the impact of UK guideline-recommended statin treatment across socioeconomic deprivation quintiles. Results: Age, sex, socioeconomic deprivation, smoking, hypertension, diabetes, and cardiovascular events were key CVD risk determinants. Model-predicted event rates corresponded well to observed rates across participant categories. The model projected strong gradients in remaining life expectancy, with 4-5-year (5-8 QALYs) gaps between the least and most socioeconomically deprived quintiles. Guideline-recommended statin treatment was projected to increase QALYs, with larger gains in quintiles of higher deprivation. Conclusion: The study demonstrated the potential of guideline-recommended statin treatment to reduce socioeconomic inequalities. This CVD model is a novel resource for individualised long-term projections of health outcomes of CVD treatments.